Exact Sciences (EXAS) Q2 Revenue Up 16%

Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, reported its Q2 2025 earnings on August 6, 2025. Revenue and GAAP earnings both exceeded analyst expectations, as new products and improved commercial execution powered performance above consensus expectations. GAAP revenue came in at $811 million for Q2 2025, above the analyst estimate of $773.8 million (GAAP), representing a 16.0% increase from the prior year’s quarter. Non-GAAP EPS reached $0.22 for Q2 2025, far exceeding the GAAP estimate of a ($0.13) loss and Non-GAAP EPS was $0.22, a 57.1% increase from Q2 2024. Adjusted EBITDA reached $138 million for Q2 2025, a 25.5% increase from Q2 2024, while raising its full-year 2025 guidance for revenue and adjusted EBITDA. This strong quarter reflected robust adoption of new cancer tests, ongoing cost controls, and advancing progress in Exact Sciences’ strategic initiatives. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Exact Sciences specializes in cancer diagnostics, focusing on developing and commercializing non-invasive screening and diagnostic tests. Its offerings include the Cologuard test for colorectal cancer and a range of precision oncology tests like Oncotype DX, which guides cancer treatment decisions. The company’s business model is centered around early cancer detection, wide market access, and driving recurring usage through physician and patient engagement.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool